Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Propensity score

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Propensity score. Displaying page 1 of 1.
    EudraCT Number: 2021-001181-38 Sponsor Protocol Number: AuspiCiOus Start Date*: 2021-07-29
    Sponsor Name:Academic Medical Center
    Full Title: Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study
    Medical condition: Gastroesophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015712-17 Sponsor Protocol Number: G080186 Start Date*: 2010-03-25
    Sponsor Name:HCRI
    Full Title: A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous cor...
    Medical condition: Dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug eluting stent (DES) or bara metal stent (BMS) placement for the treatment of corona...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10055218 Ischemic heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) DE (Completed) CZ (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007237-47 Sponsor Protocol Number: PHYDELIO Start Date*: 2009-01-15
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dysfunction Perioperative Gabe von Physostigmin bei Leberteilresktion zur Prop...
    Medical condition: The drug physostigmine will be investigated in patients (men and women)undergoing a liver resection. The study medication will be administered by intravenous infusion continuously (24 hours) to pre...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000768-27 Sponsor Protocol Number: BAY59-7939/16573 Start Date*: 2015-01-29
    Sponsor Name:Bayer HealthCare AG
    Full Title: Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients w...
    Medical condition: Embolic stroke of undetermined source (ESUS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10014498 Embolic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Prematurely Ended) PT (Prematurely Ended) CZ (Completed) BE (Completed) ES (Completed) IT (Prematurely Ended) HU (Completed) FI (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001719-65 Sponsor Protocol Number: CALC-SSc Start Date*: 2018-12-10
    Sponsor Name:University Medial Center Groningen
    Full Title: CALCification as an early marker of vasculopathy and organ involvement in Systemic Sclerosis CALC-SSc study
    Medical condition: Systemic sclerosis (SSc) is a rare progressive autoimmune disease hallmarked by severe vasculopathy. Patients are prone to enhanced calcification of skin and the vasculature. Active calcifications ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005111-16 Sponsor Protocol Number: XP-IIT-0029 Start Date*: 2015-02-16
    Sponsor Name:Instituto de Investigaciones del Sueño
    Full Title: Response to gabapentin enacarbil in two groups of RLS patients: Previously exposed to long-term treatment with dopaminergic agents versus dopaminergic treatment-naive patients.
    Medical condition: RLS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001266-29 Sponsor Protocol Number: PC-ARN-IPC-2015-025 Start Date*: 2017-02-09
    Sponsor Name:Institut Paoli Calmettes
    Full Title: Active surveillance with or without a 6 months Apalutamide treatment in low risk prostate cancer: a phase II randomized multicenter trial
    Medical condition: Low risk localized prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000346-19 Sponsor Protocol Number: HP-CD-CL-2003 Start Date*: 2018-06-04
    Sponsor Name:Herantis Pharma Plc
    Full Title: A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-C...
    Medical condition: Idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2021-001384-25 Sponsor Protocol Number: GMALL-BLIVEN Start Date*: 2021-09-28
    Sponsor Name:Goethe-Universität, vertreten durch den Präsidenten, dieser vertreten durch die LKP (bevollmächtigt durch den Sponsor)
    Full Title: An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)
    Medical condition: Philadelphia negative, CD19-positive B-precursor acute lymphoblastic leukemia: -Refractory BCP-ALL to primary induction therapy -Untreated first relapse of BCP-ALL with first remission duration < 1...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066104 Precursor B-lymphoblastic leukaemia acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023452-87 Sponsor Protocol Number: CXA-cUTI-10-04 Start Date*: 2011-08-11
    Sponsor Name:Cubist Pharmaceuticals, Inc.
    Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE SAFETY AND EFFICACY OF INTRAVENOUS CXA 201 AND INTRAVENOUS LEVOFLOXACIN IN COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELO...
    Medical condition: Complicated Urinary Tract Infection, Including Pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SK (Completed) LV (Completed) EE (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-023453-11 Sponsor Protocol Number: CXA-cUTI-10-05 Start Date*: 2011-08-04
    Sponsor Name:Cubist Pharmaceuticals, Inc.
    Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE SAFETY AND EFFICACY OF INTRAVENOUS CXA 201 AND INTRAVENOUS LEVOFLOXACIN IN COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELO...
    Medical condition: Complicated Urinary Tract Infection, Including Pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Prematurely Ended) SI (Completed) BG (Completed) EE (Prematurely Ended) LV (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:33:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA